Overall, Statista predicted the worldwide pharma industry market revenue will increase 4.5% between 2024 and 2025.
Oncology medication revenue is projected to grow 7.6%, reaching $208.86 billion in 2025. Other lucrative pharmaceutical markets in 2025 include:
- Anti-diabetes drugs — $84.48 billion (8.3% growth from 2024)
- Vaccines — $69.21 billion (-6.6%)
- Immunosuppressants — $61.05 billion (15.1%)
- Antiviral drugs — $52.19 billion (2%)
- Anti-rheumatic drugs — $47.33 billion (-0.7%)
By 2026, Statista predicted the cell therapy market will reach $87.22 billion, gene therapies will reach $13.25 billion and nucleic acid therapies will hit $1.35 billion.
Oncology is expected to account for the largest chunk of the next generation of therapeutic areas, with a projected $62.54 billion market value. The other leading therapeutic areas are expected to be multiple sclerosis ($12.66 billion) and inflammatory rheumatism ($5.77 billion).
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.